AWP
TNXP icon

Abacus Wealth Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Abacus Wealth Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,000
Closed -$362K – 513
2025
Q3 		$362K Buy
+15,000
New +$557K 0.05% 71

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Abacus Wealth Partners's TNXP Position: Q4 2025 in Review

Abacus Wealth Partners sold out of Tonix Pharmaceuticals (TNXP) in Q4 2025, closing a stake of 15,000 shares — an estimated $362K sold.

Abacus Wealth Partners first reported a position in TNXP in Q3 2025 and held it in 1 quarter. The position peaked at $362K in Q3 2025. 70 funds tracked by Wall St. Rank hold TNXP as of Q4 2025.

  • Abacus Wealth Partners reported no remaining Tonix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Abacus Wealth Partners sold 15,000 Tonix Pharmaceuticals shares in Q4 2025, an estimated $362K.
  • Abacus Wealth Partners first reported a position in Tonix Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Abacus Wealth Partners's Tonix Pharmaceuticals position peaked at $362K in Q3 2025.
  • 70 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2025.

Based on Abacus Wealth Partners's 13F filing for Q4 2025, filed 5 Feb 2026.